Testing effectiveness (Phase 2)Temporarily pausedNCT06325683
What this trial is testing
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
Who this might be right for
Progressive GlioblastomaRecurrent Glioblastoma
National Cancer Institute (NCI) 184